Hepatocellular carcinoma (HCC), the most common primary malignancy of the liver, is the sixth most common malignancy and the second leading cause of cancer-related mortality in the world (Torre LA et al (2012) CA Cancer J Clin 65, 87--108). The most curative treatment for HCC patients is surgical resection at an early stage, but very few patients are diagnosed at an early stage. Meanwhile, the cure rates for chemotherapies such as sorafenib and the receptor tyrosine kinase inhibitors (unitinib, brivanib, linifanib), are limited and show no advantages for overall survival and disease-free survival rates. Currently, some molecular biomarkers, such as α-fetoprotein (AFP), glypican 3 (GPC3), glutamine synthetase, (GS) and heat-shock protein 70 (HSP70), are available for HCC diagnosis in clinical practice, but the sensitivity and specificity are not satisfactory Therefore, the discovery of an objective molecular biomarker that would help to standardize histologic diagnosis of early-stage HCC and lead to appropriate treatment is eagerly anticipated.

Like other cancers, HCC is characterized by a multi-step process leading to tumor progression. Based on this premise, to identify early-stage HCC decision molecular features, we performed whole transcriptome assays with 107 human hepatic tissues, including normal liver (NL), fibrosis of chronic hepatitis (CH), cirrhosis (CS), low-grade dysplastic nodule (LGDN), high-grade dysplastic nodule (HGDN) and HCCs, comprising histologic gradings of Edmonson Grade 1 (G1), G2 and G3. Hierarchical clustering analysis indicated that HGDN is a precancerous lesion connoting a driver gene signature, and progresses favorably to overt HCC. Based on these results, we designed a gene selection strategy to identify gene sets that would enable us to anticipate potential HCC within a precancerous lesion such as HGDN. Using various computational approaches, we selected 10 gene elements as candidates and, through immunohistochemical staining, showed that barrier-to-autointegration factor 1 (*BANF1*), procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (*PLOD3*) and splicing factor 3b subunit 4 (*SF3B4*) are HCC diagnostic biomarkers, with superior capabilities to diagnose early-stage HCC in a large cohort of HCC patients, when compared to the currently popular trio of HCC diagnostic biomarkers i.e., *GPC3*, *GS*, and *HSP70*.

Alternative splicing (AS) is one of the main steps of the gene transcription process and contributes to proteome diversity. It is estimated that over 90% of genes have more than one transcript isoform generated through alternative splicing mechanism in humans. Several mRNA isoforms specific to certain cellular developmental states and diseases, including tumorigenesis, have been investigated. Also, several splicing factors were reported as oncogenes or tumor suppressor genes and regulate AS of genes in cancer progression. RNA splicing is regulated by two spliceosomes, the major (U2 snRNP dependent) and minor (U12 snRNP dependent) spliceosomes. U2 snRNP is composed of U2 snRNA and the splicing factor 3a, 3b (*SF3a*, *SF3b*) complex and form the major spliceosome. Among the six subunits of the *SF3b* complex, only *SF3B4* was identified to be the most upregulated gene in HCC patients from the gene expression analyses of The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA_LIHC) data collection and the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). In addition, *SF3B4* was also frequently amplified (amplification: 11%, gain: 60%) in HCC patients and the expression and copy number values were highly correlated (Pearson *r* = 0.64).

To investigate the biological function of *SF3B4* in HCC, we performed RNAi-mediated gene knockdown followed by several cell phenotype assays. Target disruption of *SF3B4* showed inhibition of HCC cell growth, proliferation, migration and invasion *in vitro*. *SF3B4* knockdown induced G1 phase cell cycle arrest, not apoptosis, through upregulating of p27^Kip1^ and down-regulating of cyclins and CDKs in HCC cells. To investigate whether SF3B4 upregulation could induce alternative splicing in HCC, we performed AS analysis of *SF3B4* knockdown- or Spliceostatin A (SSA, a SF3b complex inhibitor)-treated HCC cells. Both *SF3B4* knockdown and SSA-treated cells exhibited aberrant vascular endothelial growth factor (*VEGF*) gene alternative splicing event and resulted in the suppression of wild-type *VEGF* and accordingly, upregulation of *VEGF* pre-mRNA in HCC cells. Next, to investigate the direct target of *SF3B4* in hepatocarcinogenesis, we analyzed the NGS RNA-seq data of the *SF3B4* knockdown HepG2 cells available from the GEO database (GSE80861), and we identified 8 gene elements that are upregulated in HCC, with frequent AS events. After experimental validation in five different HCC cell lines, we found that kruppel-like factor 4 (*KLF4*) was directly regulated by *SF3B4* in HCC cells. Direct sequencing analysis confirmed that the two non-functional alternative *KLF4* transcripts were generated through skipped exon (SE) alternative splicing event. The dual luciferase reporter assay also demonstrated that KLF4 regulates *p27^Kip1^* and *Slug* expression by direct binding to their promoter regions. These results suggest that inactivation of KLF4 through aberrant expression of SF3B4 contributes to malignant transformation and growth of hepatocyte via transcriptional inactivation of *p27^Kip1^* and simultaneously activated *Slug* ([Diagram 1](#f1-bmb-51-057){ref-type="fig"}).

Alternative splicing has been reported as an important mechanism in tumorigenesis in many cancers, and inhibitors for splicing factors were considered as new drugs for cancer therapy. Several natural products (like FR901464, Herboxidiene and Pladienolides) targeting the SF3b complex were reported to show anticancer effects, with low half maximal inhibitory concentrations (IC~50~) and cytotoxic effects in animal models. EA. Obeng *et al* showed that Sf3b1^K700E^ expression causes earlier onset of myelodysplastic syndrome (MDS) and develop macrocytic anemia and myelodysplasia in mice. Furthermore, cells expressing *Sf3b1^K700E^* showed more sensitivity (IC~50~ = 0.619 nM) to E7107 than cells expressing wild-type Sf3b*1* (IC~50~ = 1.249 nM) in a mouse MDS model (EA. Obeng *et al* (2016) Cancer Cell 30, 404--417). In our study, we intravenously delivered the SF3B4-specific siRNA using nanoparticles to H-*ras* transgenic mice, which spontaneously develop HCC. Our results showed that the mice injected with SF3B4-specific siRNA developed liver tumors much more tardily and smaller than that of the control-group (control siRNAs) mice. Overall, our findings suggest that novel molecular biomarkers, *BANF1*, *PLOD3* and *SF3B4* indicating early-stage HCC in a precancerous lesion, and that aberrantly over-expressed *SF3B4* plays an important role as a cancer driver gene at early-stage of HCC and regulates the expression of many cancer-associated genes through an AS mechanism. AS is a considerable mechanism for cancer development and inhibition of AS may be a promising therapeutic strategy for HCC and many other cancers.
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